Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Rising Dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability of TAK-788 Followed by Open-Label, Crossover Evaluation of the Effects of a Low-Fat Meal on TAK-788 Pharmacokinetics and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2019
At a glance
- Drugs TAK 788 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda Oncology
- 04 Feb 2019 Status changed from active, no longer recruiting to completed.
- 21 Nov 2018 Number of arms and patient number has been increaed.
- 21 Nov 2018 Planned End Date changed from 18 Jan 2019 to 17 Jan 2019.